ATE419875T1 - Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha - Google Patents

Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha

Info

Publication number
ATE419875T1
ATE419875T1 AT02776411T AT02776411T ATE419875T1 AT E419875 T1 ATE419875 T1 AT E419875T1 AT 02776411 T AT02776411 T AT 02776411T AT 02776411 T AT02776411 T AT 02776411T AT E419875 T1 ATE419875 T1 AT E419875T1
Authority
AT
Austria
Prior art keywords
human
dose
tnf
sarcoma
alpha
Prior art date
Application number
AT02776411T
Other languages
English (en)
Inventor
Henrik Rasmussen
Karen Chu
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21693977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419875(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genvec Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE419875T1 publication Critical patent/ATE419875T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02776411T 2001-11-02 2002-11-01 Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha ATE419875T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/001,017 US20030086903A1 (en) 2001-11-02 2001-11-02 Therapeutic regimen for treating cancer
US10/151,633 US7214368B2 (en) 2001-11-02 2002-05-17 Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-α transgene

Publications (1)

Publication Number Publication Date
ATE419875T1 true ATE419875T1 (de) 2009-01-15

Family

ID=21693977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776411T ATE419875T1 (de) 2001-11-02 2002-11-01 Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha

Country Status (7)

Country Link
US (5) US20030086903A1 (de)
EP (1) EP1455840B1 (de)
JP (1) JP2005536447A (de)
AT (1) ATE419875T1 (de)
CA (1) CA2465361A1 (de)
DE (1) DE60230807D1 (de)
WO (1) WO2003039458A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8034791B2 (en) * 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20040266713A1 (en) * 2003-04-23 2004-12-30 Shan Lu Methods and compositions for solid tumor treatment
US20050027196A1 (en) * 2003-07-30 2005-02-03 Fitzgerald Loretta A. System for processing patient radiation treatment data
DE602004025726D1 (de) 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
EP2298412A1 (de) 2004-02-12 2011-03-23 Neovista, Inc. Vorrichtung für die intraokulare Brachytherapie
US7563222B2 (en) 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
EP1781284B1 (de) * 2004-08-25 2010-10-13 The University of Chicago Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
US8586090B2 (en) * 2004-10-05 2013-11-19 Albert Einstein College Of Medicine Of Yeshiva University Melanin nanoshells for protection against radiation and electronic pulses
BRPI0618677A2 (pt) 2005-11-15 2011-09-06 Neovista Inc métodos e aparelho para braquiterapia intra-ocular
US10166271B2 (en) * 2006-06-21 2019-01-01 The Regents Of The University Of California Methods for promoting hair growth
US8620041B2 (en) * 2007-12-31 2013-12-31 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
JP5837748B2 (ja) * 2007-12-31 2015-12-24 リアル イメージング リミテッド 撮像データのレジストレーションのためのシステムおよび方法
WO2009118721A1 (en) * 2008-03-28 2009-10-01 Real Imaging Ltd. Method apparatus and system for analyzing thermal images
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR20120139672A (ko) 2009-11-09 2012-12-27 젠벡, 인코포레이티드 원숭이 아데노바이러스 벡터의 증식 방법
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法
JP2017525370A (ja) * 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0155549B1 (de) 1984-03-06 1991-03-20 Dainippon Pharmaceutical Co., Ltd. DNS den menschlichen Tumornekrosisfaktor kodierend und das menschliche Tumornekronisfaktor-Polypeptid
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JP3203599B2 (ja) * 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
CA2055168A1 (en) * 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5968735A (en) * 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
US5271207A (en) * 1992-11-18 1993-12-21 Moshe Epstein Dual-function nozzle head for vacuum-packaging tooling
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US7592317B1 (en) * 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
AU4994596A (en) 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
WO1996033746A1 (en) 1995-04-28 1996-10-31 Genetic Therapy, Inc. Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
EE9800160A (et) 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
WO1997039135A1 (en) 1996-04-17 1997-10-23 Board Of Regents, The University Of Texas System Enhanced expression of transgenes
EP0979101B1 (de) 1996-07-03 2010-10-27 Merial, Inc. Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
IL120979A0 (en) 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
CA2303401A1 (en) 1997-10-01 1999-04-08 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
CA2308511C (en) 1997-10-29 2016-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of transfected or transduced mammalian cells for treating bone pathologies
DE19747718A1 (de) 1997-10-29 1999-05-06 Baltzer Axel Wilhelm August Dr Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie
KR20010031762A (ko) 1997-11-03 2001-04-16 추후제출 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
JP2002506651A (ja) 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
AU772963B2 (en) 1998-04-24 2004-05-13 Onyx Pharmaceuticals Adenoviral vectors for treating disease
AU762615B2 (en) 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
IL126757A0 (en) 1998-09-07 1999-08-17 Yissum Res Dev Co Regulation of gene expression through manipulation of mRNA splicing and its uses
US6440944B2 (en) 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
ES2325303T3 (es) 1999-01-28 2009-09-01 Onyx Pharmaceuticals, Inc. Vectores adenoviricos lanzadera con e1b suprimida.
EP1223952B1 (de) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1390075B1 (de) 2001-04-06 2012-01-18 The University of Chicago Chemotherapeutische einleitung der egr-1-promoter-aktivität in gentherapie
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer

Also Published As

Publication number Publication date
EP1455840B1 (de) 2009-01-07
US20030086903A1 (en) 2003-05-08
JP2005536447A (ja) 2005-12-02
DE60230807D1 (de) 2009-02-26
CA2465361A1 (en) 2003-05-15
WO2003039458A2 (en) 2003-05-15
US7214368B2 (en) 2007-05-08
WO2003039458A3 (en) 2003-11-20
US20120203052A1 (en) 2012-08-09
US20030086904A1 (en) 2003-05-08
US20100305199A1 (en) 2010-12-02
US20070166284A1 (en) 2007-07-19
EP1455840A4 (de) 2004-12-15
EP1455840A2 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DE60230807D1 (de) Behandlung von sarkom bei menschen mit adenovirus-vektor tnf-alpha
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
HRP20010877B1 (hr) Pripravci za prevenciju i liječenje amiloidogenskih bolesti
EA200300294A1 (ru) Способы лечения связанного с bcl-2 нарушения с использованием bcl-2-антисмысловых олигомеров
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE69731540D1 (de) Behandlung von diarrhoe
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
ATE419370T1 (de) Lentivirale vektoren zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties